PRESS RELEASE AB SCIENCE ANNOUNCES A NEW PUBLICATION ON BIORXIV THAT IDENTIFIES AND CHARACTERIZES A NOVEL SMALL SYNTHETIC MOLECULE, AB8939, AS A PROMISING DRUG CANDIDATE FOR TREATING REFRACTORY ACUTE ...
1 小时on MSN
Clinical trial of personalized cancer vaccine demonstrates feasibility, safety, immune ...
The first-in-human clinical phase I trial assessing the feasibility and safety of WDVAX, an immunostimulatory ...
Scientists have identified a promising strategy to improve liver cancer immunotherapy: targeting B-cells. While immunotherapy ...
Dr. Wen-Han Chang, corresponding author, added, “The work highlights why biomarkers cannot be interpreted in isolation. Tumor context—immune composition, metabolic state, and innate ...
Milestone Triggers Release of Shares to Kintara Contingent Value Right (CVR) HoldersTAMPA, Fla., Dec. 15, 2025 /PRNewswire/ - ...
The American Society of Hematology/ASH 2025 meeting included AML results from AAML1831, MyeChild01, BIG-1, and PALG-AML1/2016 studies.
Detailed price information for Ventripoint Diagnostics Ltd (VPT-X) from The Globe and Mail including charting and trades.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈